Carly Milliner, in Fishers, IN - Medicare Speech-Language Pathologist Provider

Carly Milliner, is a medicare enrolled "Speech-language Pathologist" provider in Fishers, Indiana. Her current practice location is 11570 E 126th St, Fishers, Indiana. You can reach out to her office (for appointments etc.) via phone at (317) 204-3736.

Carly Milliner is licensed to practice in * (Not Available) (license number ) and she also participates in the medicare program. She does not accept medicare assignments directly but she may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. Her NPI Number is 1215444542.

Contact Information

	Carly Milliner,
	11570 E 126th St, Fishers, IN 46037-9592
	(317) 204-3736
	Not Available

Healthcare Provider's Profile

Full Name	Carly Milliner
Gender	Female
Speciality	Speech-language Pathologist
Location	11570 E 126th St, Fishers, Indiana
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1215444542
Provider Enumeration Date: 01/09/2018
Last Update Date: 05/16/2022

Medicare PECOS Information:

PECOS PAC ID: 3779998406
Enrollment ID: I20210210002682

Medical Identifiers

Medical identifiers for Carly Milliner such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1215444542	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	2017024477 (Missouri)	Secondary
235Z00000X	Speech-language Pathologist	(* (Not Available))	Primary

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Carly Milliner allows following entities to bill medicare on her behalf.

Provider Name	Creative Health Care Management Llc
Provider Type	Part B Supplier - Clinic/group Practice
Provider Identifiers	NPI Number: 1902350457 PECOS PAC ID: 4385929892 Enrollment ID: O20170324001139

News Archive

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra or Remsima).

U.S. FDA approves Gilead's Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

Microsoft, Visionshare partner to enhance health information transaction between physicians, patients

VisionShare, the nation's largest and most trusted healthcare information network, announced today that it is working with Microsoft Corp. to enhance the transaction of health information from physicians to their patients based on security protocols endorsed by the Office of the National Coordinator's Direct Project.

Scientists find new mechanism for guiding growth of nerves

A new mechanism for guiding the growth of nerves that involves cell-death machinery has been found by scientists at the University of Nevada, Reno that may bring advances in neurological medicine and research.

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

CeNeRx BioPharma, Inc. has announced issuance of a new U.S. patent covering its novel compounds that selectively target peripheral cannabinoid receptors.

Provider Name	Priority Wellness And Rehab Llc
Provider Type	Part B Supplier - Physical/occupational Therapy Group In Private Practice
Provider Identifiers	NPI Number: 1326686049 PECOS PAC ID: 0749619799 Enrollment ID: O20200326002890

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

U.S. FDA approves Gilead's Truvada to minimize risk of sexually-acquired HIV infection

Microsoft, Visionshare partner to enhance health information transaction between physicians, patients

Scientists find new mechanism for guiding growth of nerves

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

CeNeRx BioPharma, Inc. has announced issuance of a new U.S. patent covering its novel compounds that selectively target peripheral cannabinoid receptors.

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Carly Milliner is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Carly Milliner, 16763 Lakeville Xing, Westfield, IN 46074-8208 Ph: () -	Carly Milliner, 11570 E 126th St, Fishers, IN 46037-9592 Ph: (317) 204-3736

News Archive

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

U.S. FDA approves Gilead's Truvada to minimize risk of sexually-acquired HIV infection

Microsoft, Visionshare partner to enhance health information transaction between physicians, patients

Scientists find new mechanism for guiding growth of nerves

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

CeNeRx BioPharma, Inc. has announced issuance of a new U.S. patent covering its novel compounds that selectively target peripheral cannabinoid receptors.

Speech-Language Pathologist in Fishers, IN

Mrs. Lori Beth Henderson, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12344 Quarry Face Ct, Fishers, IN 46037 Phone: 317-841-3528
Dree Ellingworth, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10294 E 96th St, Fishers, IN 46037 Phone: 515-460-0537
Amy Grimes, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8920 Tynan Way, Fishers, IN 46038 Phone: 317-207-1613
Megan Elizabeth Rector, M.A., CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 10280 Tournon Dr, Fishers, IN 46037 Phone: 812-987-4229
Allyson Starks, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9957 Allisonville Rd, Fishers, IN 46038 Phone: 317-841-7005
Rachel Schaller, SPEECH LANGUAGE PATH Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12882 Longleaf Lane, Fishers, IN 46038 Phone: 317-771-5459
Mrs. Kristina Rene Sturwold, MA, CCC, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9714 Fortune Dr, Fishers, IN 46037 Phone: 317-849-1409 Fax: 317-576-8084

Carly Milliner, - Medicare Speech-Language Pathologist in Fishers, IN

Contact Information

Healthcare Provider's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medicare Reassignments

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

U.S. FDA approves Gilead's Truvada to minimize risk of sexually-acquired HIV infection

Microsoft, Visionshare partner to enhance health information transaction between physicians, patients

Scientists find new mechanism for guiding growth of nerves

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

U.S. FDA approves Gilead's Truvada to minimize risk of sexually-acquired HIV infection

Microsoft, Visionshare partner to enhance health information transaction between physicians, patients

Scientists find new mechanism for guiding growth of nerves

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

U.S. FDA approves Gilead's Truvada to minimize risk of sexually-acquired HIV infection

Microsoft, Visionshare partner to enhance health information transaction between physicians, patients

Scientists find new mechanism for guiding growth of nerves

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

Speech-Language Pathologist in Fishers, IN